Literature DB >> 19210908

Irreversible airway obstruction in asthma.

Louis-Philippe Boulet1.   

Abstract

Asthma is generally characterized by fully reversible airway obstruction. However, a significant proportion of asthma patients demonstrate an incomplete reversibility of airway obstruction (IRAO) despite optimal treatment and the absence of a significant smoking history. Such partially irreversible airway obstruction may be due to residual airway inflammation, particularly of the eosinophilic type, and structural changes. Risks factors for IRAO include reduced pulmonary function early in life, frequent exacerbations, smoking, continuing exposure to a sensitizing agent, and adult-onset asthma. IRAO is associated with increased disease severity and increased asthma-related morbidity and mortality. Optimal asthma control, including prevention of asthma exacerbations, smoking avoidance, and sufficient anti-inflammatory therapy, should be implemented in an effort to avoid an accelerated decline in lung function and the development or worsening of IRAO.

Entities:  

Mesh:

Year:  2009        PMID: 19210908     DOI: 10.1007/s11882-009-0025-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  69 in total

Review 1.  The Melbourne Asthma Study: 1964-1999.

Authors:  Peter D Phelan; Colin F Robertson; Anthony Olinsky
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

2.  Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma.

Authors:  H Jongepier; H M Boezen; A Dijkstra; T D Howard; J M Vonk; G H Koppelman; S L Zheng; D A Meyers; E R Bleecker; D S Postma
Journal:  Clin Exp Allergy       Date:  2004-05       Impact factor: 5.018

Review 3.  Asthma: defining of the persistent adult phenotypes.

Authors:  Sally E Wenzel
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

Review 4.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

5.  Irreversible airflow obstruction. Evolution in asthma.

Authors:  K E Finucane; H W Greville; P J Brown
Journal:  Med J Aust       Date:  1985-05-27       Impact factor: 7.738

6.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma.

Authors:  G W Chalmers; K J Macleod; S A Little; L J Thomson; C P McSharry; N C Thomson
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

7.  Mortality and airflow obstruction in asthma: a 17-year follow-up study.

Authors:  J A Panizza; A L James; G Ryan; N de Klerk; K E Finucane
Journal:  Intern Med J       Date:  2006-12       Impact factor: 2.048

8.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.

Authors: 
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

9.  Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.

Authors:  June H Lee; Tmirah Haselkorn; Larry Borish; Lawrence Rasouliyan; Bradley E Chipps; Sally E Wenzel
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

10.  Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma.

Authors:  I H van Veen; A Ten Brinke; P J Sterk; J K Sont; S A Gauw; K F Rabe; E H Bel
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

View more
  4 in total

1.  μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model.

Authors:  Sumit Ghosh; Scott A Hoselton; Jane M Schuh
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

Review 2.  Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Matt Stevenson; Katy Cooper; Sue Harnan; Jean Hamilton; Mark Clowes; Christopher Carroll; Tim Harrison; Shironjit Saha
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

3.  Fms-like tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and -challenged mice.

Authors:  Halvor S McGee; Arthur L Stallworth; Tanupriya Agrawal; Zhifei Shao; Lindsey Lorence; Devendra K Agrawal
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

4.  Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3.

Authors:  James G Krings; Charles W Goss; Daphne Lew; Maanasi Samant; Mary Clare McGregor; Jonathan Boomer; Leonard B Bacharier; Ajay Sheshadri; Chase Hall; Joshua Brownell; Ken B Schechtman; Samuel Peterson; Stephen McEleney; David T Mauger; John V Fahy; Sean B Fain; Loren C Denlinger; Elliot Israel; George Washko; Eric Hoffman; Sally E Wenzel; Mario Castro
Journal:  J Allergy Clin Immunol       Date:  2021-02-09       Impact factor: 14.290

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.